A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses (Q30226740)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses |
scientific article |
Statements
1 reference
A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses (English)
1 reference
Jiri Beran
1 reference
Ibrahim A Abdel-Messih
1 reference
Jolana Raupachova
1 reference
Lenka Hobzova
1 reference
Elena Fragapane
1 reference
1 December 2010
1 reference
1 reference
Identifiers
1 reference